Effectiveness of paclitaxel-eluting stents in complex clinical patients: Insights from the TAXUS Japan postmarket surveillance study

Circulation Journal

Volumn 75, Issue 11, 2011, Pages 2573-2580

  Nakamura, Masato ^a   Kotani, Jun Ichi ^b   Kozuma, Ken ^c   Uchida, Takahiro ^d   Iwabuchi, Masashi ^e   Muramatsu, Toshiya ^f   Hirayama, Haruo ^g   Fujii, Kenshi ^h   Saito, Shigeru ⁱ  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c TEIKYO UNIVERSITY HOSPITAL   (Japan)

^d BOSTON SCIENTIFIC CORPORATION   (United States)

^e KOKURA MEMORIAL HOSPITAL   (Japan)

^f SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^g NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^h Sakurabashi Watanabe Hospital   (Japan)

ⁱ Shounan Kamakura Hospital   (Japan)

Author keywords

Diabetes mellitus; Hemodialysis; Stents

Indexed keywords

INSULIN; PACLITAXEL;

AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SURVEILLANCE PROGRAM; FEMALE; HEART DEATH; HEART INFARCTION; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION;

AGED; ANGIOPLASTY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DEATH; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PREVALENCE; PRODUCT SURVEILLANCE, POSTMARKETING; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80054981580     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0320     Document Type: Article

References (32)

1. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbæk H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007; 356: 1030-1039.
2. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, et al. Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis. BMJ 2008; 337: a1331.
3. Cheng CI, Lee FY, Chang JP, Hsueh SK, Hsieh YK, Fang CY, et al. Long-term outcomes of intervention for unprotected left main coronary artery stenosis coronary stenting vs coronary artery bypass grafting. Circ J 2009; 73: 705-712.
4. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1172-1179.
5. Lee SR, Jeong MH, Ahn YK, Chae SC, Hur SH, Kim YJ, et al. Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry. Circ J 2008; 72: 392-398.
6. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
7. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997.
8. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
9. European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
10. Aoyama T, Ishii H, Toriyama T, Takahashi H, Kasuga H, Murakami R, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 2008; 72: 56-60.
11. Nakamura M, Yokoi H, Hamazaki Y, Watarai M, Kijima M, Mitsudo K, et al. Impact of insulin-treated diabetes and hemodialysis on longterm clinical outcomes following sirolimus-eluting stent deployment: Insights from a sub-study of The Cypher Stent Japan Post-Marketing Surveillance (Cypher J-PMS) Registry. Circ J 2010; 74: 2592-2597.
12. Otsuka M, Toyofuku M, Watanabe N, Motoda C, Kawase T, Takeda R, et al. Clinical usefulness of drug-eluting stents in the treatment of dialysis patients with coronary artery disease. EuroIntervention 2011; 6: 754-759.
13. Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus-or paclitaxel-eluting stents: Results From the SPIRIT IV Clinical Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010; 56: 2084-2089.
14. Carter AJ. TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv 2004; 61: 233-236.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
16. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-535.
17. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102: 2180-2184.
18. Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ. Unstable angina: A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995; 92: 1731-1736.
19. Vavuranakis M, Stefanadis C, Toutouzas K, Pitsavos C, Spanos V, Toutouzas P. Impaired compensatory coronary artery enlargement in atherosclerosis contributes to the development of coronary artery stenosis in diabetic patients. Eur Heart J 1997; 18: 1090-1094.
20. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
21. Kim MH, Hong SJ, Cha KS, Park HS, Chae SC, Hur SH, et al. Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv Cardiol 2008; 21: 225-231.
22. Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: The Diabetes and Drug-Eluting Stent (DiabeDES) randomized angiography trial. Am J Cardiol 2009; 103: 345-349.
23. Fröbert O, Lagerqvist B, Carlsson J, Lindbäck J, Stenestrand U, James SK. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: A Report From the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009; 53: 1660-1667.
24. Hanna NN, Gaglia MA Jr, Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, et al. Three-year outcomes following sirolimus-versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 2010; 106: 504-510.
25. Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, et al. The unrestricted use of sirolimus-and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than baremetal stents: An analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) Registries. JACC Cardiovasc Interv 2010; 3: 1051-1058.
26. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized comparison of sirolimus-versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 4-year clinical outcomes of DES-DIABETES (Drug-Eluting Stent in patients with DIABETES mellitus) trial. JACC Cardiovasc Interv 2011; 4: 310-316.
27. Hong SJ, Kim MH, Cha KS, Park HS, Chae SC, Hur SH, et al. Comparison of three-year clinical outcomes between sirolimusversus paclitaxel-eluting stents in diabetic patients: Prospective randomized multicenter trial. Catheter Cardiovasc Interv 2010; 76: 924-933.
28. Grube E. SPIRIT V Diabetic RCT: 9 month angiographic and 1 year clinical follow-up. EuroPCR: Paris, France; 2010.
29. Tada T, Kimura T, Morimoto T, Ono K, Furukawa Y, Nakagawa Y, et al. Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulintreated diabetic, and non-diabetic patients from J-Cypher Registry. Am J Cardiol 2011; 107: 1155-1162.
30. Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009; 2: 1248-1259.
31. Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: Results from the TAXUS-IV trial. J Am Coll Cardiol 2006; 48: 32-36.
32. Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: A critical assessment of "Oculostenotic" reintervention in patients with intermediate lesions. JACC Cardiovasc Interv 2010; 3: 403-411.